BRAF and non-small cell lung carcinoma: BRAF V600E mutations are found in 1–3% of NSCLC and are sensitive to treatment with a combination of BRAF inhibitors and dabrafenib (Tafinlar, Novartis Europharm) in combination with trametinib (Mekinist, Novartis Europharm) after progression on chemotherapy [8].